Shirt a Phobia

Sample Page

Gemlapodect (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette’s syndrome and speech disorders.[1][2][3] It is taken orally.[1] The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons.[3] Gemlapodect was originated by Roche and is under development by Noema Pharma.[1][2] As of September 2025, it is in phase 2 clinical trials for both Tourette’s syndrome and speech disorders.[1][2]

See also

References

  1. ^ a b c d e “Noema Pharma”. AdisInsight. 18 September 2025. Retrieved 2 June 2026.
  2. ^ a b c “Delving into the Latest Updates on Gemlapodect with Synapse”. Synapse. 10 March 2026. Retrieved 2 June 2026.
  3. ^ a b Häge A, Krämer R, Dunlap M, Mechler K, Müller-Vahl KR, Nagy P (June 2025). “Emerging therapeutic approaches for Tourette syndrome and other tic disorders – a systematic review of current clinical trials”. European Child & Adolescent Psychiatry. 34 (6): 1719–1729. doi:10.1007/s00787-024-02637-x. PMID 39714607.